Mont-Saint-Guibert, Belgium – Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, today announced the selection of three abstracts for poster presentation at the upcoming 24th Congress of the European Hematology Association (EHA) in Amsterdam, The Netherlands, on June 13-16, 2019, including updated data from the THINK and DEPLETHINK Phase 1 trials evaluating the company’s autologous NKG2D-based CAR-T therapy CYAD-01 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndrome (MDS).
Clinical Presentation
Title: Updated Results from the Phase 1 Trials Assessing a NKG2D CAR T-Cell Approach in Relapsed/Refractory Acute Myeloid Leukimia and Myelodysplastic Syndrome Patients. Download the poster
Abstract: PS1212
Session: Gene therapy, cellular immunotherapy and vaccination – Clinical
Date: Saturday, June 15th
Time: 5:30 – 7:00 p.m. CEST (Poster Area)
Preclinical Presentations
Title: Development of a Next Generation Allogeneic CAR-T Cell Platform Without Gene Editing. Download the poster.
Abstract: PS1210
Session: Gene therapy, cellular immunotherapy and vaccination – Biology & Translational Research
Date: Saturday, June 15th
Elevator pitch: 4:30 – 4:45 p.m. CEST (Hall G106)
Time: 5:30 – 7:00 p.m. CEST (Poster Area)
Title: Modeling NKG2D-based CAR-T Cell Therapy in Animals with Acute Myeloid Leukemia. Download the poster
Abstract: PS974
Session: Acute myeloid leukemia – Biology & Translational Research
Date: Saturday, June 15th
Time: 5:30 – 7:00 p.m. CEST (Poster Area)
